LLY•benzinga•
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Summary
Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga